Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 13, 2013 - Issue 11
Submit an article Journal homepage
194
Views
5
CrossRef citations to date
0
Altmetric
Drug Profiles

The role of extended-release quetiapine fumarate monotherapy in the treatment of patients with major depressive disorder

Richard WeislerDepartment of Psychiatry, University of North Carolina at Chapel Hill, Raleigh, NC, USA;Department of Psychiatry & Behavioral Science, Duke University Medical Center, Durham, NC, USACorrespondence[email protected]
&
Roger S McIntyreDepartment of Psychiatry, University Health Network, Toronto Western Hospital, Toronto, ON, Canada
Pages 1161-1182 | Published online: 09 Jan 2014

References

  • American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th Edition), Text Revision. American Psychiatric Association, Washington, DC, USA (2000).
  • Andersen I, Thielen K, Bech P, Nygaard E, Diderichsen F. Increasing prevalence of depression from 2000 to 2006. Scand. J. Public Health 39(8), 857–863 (2011).
  • Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 62(6), 617–627 (2005).
  • Oquendo MA, Galfalvy H, Russo S et al. Prospective study of clinical predictors of suicidal acts after a major depressive episode in patients with major depressive disorder or bipolar disorder. Am. J. Psychiatry 161(8), 1433–1441 (2004).
  • Mann JJ. Neurobiology of suicidal behaviour. Nat. Rev. Neurosci. 4(10), 819–828 (2003).
  • Ten Doesschate MC, Koeter MW, Bockting CL, Schene AH. Health related quality of life in recurrent depression: a comparison with a general population sample. J. Affect. Disord. 120(1–3), 126–132 (2010).
  • Barnett PA, Gotlib IH. Psychosocial functioning and depression: distinguishing among antecedents, concomitants, and consequences. Psychol. Bull. 104(1), 97–126 (1988).
  • Greenberg PE, Kessler RC, Birnbaum HG et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J. Clin. Psychiatry 64(12), 1465–1475 (2003).
  • Sobocki P, Jonsson B, Angst J, Rehnberg C. Cost of depression in Europe. J. Ment. Health Policy Econ. 9(2), 87–98 (2006).
  • Trivedi MH, Rush AJ, Wisniewski SR et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry 163(1), 28–40 (2006).
  • Anderson IM, Ferrier IN, Baldwin RC et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J. Psychopharmacol. 22(4), 343–396 (2008).
  • Bauer M, Bschor T, Pfennig A et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. World J. Biol. Psychiatry 8(2), 67–104 (2007).
  • Glick ID, Murray SR, Vasudevan P, Marder SR, Hu RJ. Treatment with atypical antipsychotics: new indications and new populations. J. Psychiatr. Res. 35(3), 187–191 (2001).
  • Howland RH, Shutt LS, Berman SR, Spotts CR, Denko T. The emerging use of technology for the treatment of depression and other neuropsychiatric disorders. Ann. Clin. Psychiatry 23(1), 48–62 (2011).
  • Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am. J. Psychiatry 166(9), 980–991 (2009).
  • Komossa K, Depping AM, Gaudchau A, Kissling W, Leucht S. Second-generation antipsychotics for major depressive disorder and dysthymia. Cochrane Database Syst. Rev. 12, CD008121 (2010).
  • Kahn RS, Schulz SC, Palazov VD et al. Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry 68(6), 832–842 (2007).
  • Mullen J, Jibson MD, Sweitzer D. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clin. Ther. 23(11), 1839–1854 (2001).
  • Addington DE, Mohamed S, Rosenheck RA et al. Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. J. Clin. Psychiatry 72(1), 75–80 (2011).
  • Cutler AJ, Datto C, Nordenhem A, Minkwitz M, Acevedo L, Darko D. Extended-release quetiapine as monotherapy for the treatment of adults with acute mania: a randomized, double-blind, 3-week trial. Clin. Ther. 33(11), 1643–1658 (2011).
  • Vieta E, Mullen J, Brecher M, Paulsson B, Jones M. Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies. Curr. Med. Res. Opin. 21(6), 923–934 (2005).
  • Calabrese JR, Keck PE Jr, Macfadden W et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am. J. Psychiatry 162(7), 1351–1360 (2005).
  • McElroy SL, Weisler RH, Chang W et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J. Clin. Psychiatry 71(2), 163–174 (2010).
  • Suppes T, Datto C, Minkwitz M, Nordenhem A, Walker C, Darko D. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. J. Affect. Disord. 121(1–2), 106–115 (2010).
  • Thase ME, Macfadden W, Weisler RH et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J. Clin. Psychopharmacol. 26(6), 600–609 (2006).
  • Young AH, McElroy SL, Bauer M et al. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J. Clin. Psychiatry 71(2), 150–162 (2010).
  • Suppes T, Vieta E, Liu S, Brecher M, Paulsson B. Maintenance treatment for patients with bipolar I disorder: results from a North American study of quetiapine in combination with lithium or divalproex (trial 127). Am. J. Psychiatry 166(4), 476–488 (2009).
  • Vieta E, Suppes T, Eggens I, Persson I, Paulsson B, Brecher M. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J. Affect. Disord. 109(3), 251–263 (2008).
  • Weisler RH, Nolen WA, Neijber A, Hellqvist A, Paulsson B. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study). J. Clin. Psychiatry 72(11), 1452–1464 (2011).
  • Young AH, McElroy SL, Olausson B, Paulsson B. A randomised, placebo-controlled 52-week trial of continued quetiapine treatment in recently depressed patients with bipolar I and bipolar II disorder. World J. Biol. Psychiatry doi:10.3109/15622975.2012.665177 (2012) ( Epub ahead of print).
  • Goldstein JM, Arvanitis LA. ICI 204,636 (SEROQUEL™): a dibenzothiazepine atypical antipsychotic. Review of preclinical pharmacology and highlights of phase II clinical trials. CNS Drug Rev. 1(1), 50–73 (1995).
  • Jensen NH, Rodriguiz RM, Caron MG, Wetsel WC, Rothman RB, Roth BL. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT(1A) agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology 33(10), 2303–2312 (2008).
  • Nyberg S, Widzowski D. Translational pharmacology of quetiapine and norquetiapine: preclinical findings support multifunctional psychotropic properties. Eur. Psychiatry 25 ( Suppl. 1), 1446 (2010).
  • Roth BL, Sheffler D, Potkin SG. Atypical antipsychotic drug actions: unitary or multiple mechanisms for 'atypicality'? Clin. Neurosci. Res. 3(1–2), 108–117 (2003).
  • Seeman P. Atypical antipsychotics: mechanism of action. Can. J. Psychiatry 47(1), 27–38 (2002).
  • Goldstein JM, Nyberg S, Brecher M. Preclinical mechanisms for the broad spectrum of antipsychotic, antidepressant and mood stabilizing properties of Seroquel. Eur. Psychiatry 23( Suppl. 23), 202 (2008).
  • Stahl S. Psychopharmacology of Antidepressants. Martin Dunitz Ltd, London, UK (2008).
  • Hudzik T, Zhou J, Brockel B et al. Further characterization of norquetiapine and quetiapine in rodent models of antidepressant and anxiolytic action. Eur. Psychiatry 18( Suppl. 18), S351–S352 (2008).
  • Bjorkholm C, Jardemark K, Marcus MM et al. Role of concomitant inhibition of the norepinephrine transporter for the antipsychotic effect of quetiapine. Eur. Neuropsychopharmacol. 23(7), 709–720 (2013).
  • Nyberg S, Takano A, Jucaite A et al. PET-measured occupancy of the NET by extended release quetiapine fumarate (quetiapine XR) in brains of healthy subjects. Eur. Neuropsychopharmacol. 18(4), S270 (2008).
  • Hirschfeld RM, Montgomery SA, Aguglia E et al. Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J. Clin. Psychiatry 63(9), 826–837 (2002).
  • Goldstein JM. The new generation of antipsychotic drugs: how atypical are they? Int. J. Neuropsychopharmacol. 3(4), 339–349 (2000).
  • Datto C, Berggren L, Patel JB, Eriksson H. Self-reported sedation profile of immediate-release quetiapine fumarate compared with extended-release quetiapine fumarate during dose initiation: a randomized, double-blind, crossover study in healthy adult subjects. Clin. Ther. 31(3), 492–502 (2009).
  • Figueroa C, Brecher M, Hamer-Maansson JE, Winter H. Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release. Prog. Neuropsychopharmacol. Biol. Psychiatry 33(2), 199–204 (2009).
  • Juckel G, Winter HR, Ståhle L, Miller F, Strid S. The pharmacokinetics of extended release quetiapine fumarate are not affected by a light meal. Schizophr. Res. 98( Suppl.), 163 (2008).
  • DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin. Pharmacokinet. 40(7), 509–522 (2001).
  • Nemeroff CB, Kinkead B, Goldstein J. Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. J. Clin. Psychiatry 63( Suppl. 63), 5–11 (2002).
  • Wang JS, Zhu HJ, Markowitz JS, Donovan JL, DeVane CL. Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl.) 187(4), 415–423 (2006).
  • Earley W, McIntyre A, Wang G, Raines S, Eriksson H. Double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder (MDD). Int. J. Psychiatry Clin. Pract. 12(4), 332 (2008).
  • Cutler AJ, Montgomery SA, Feifel D, Lazarus A, Åström M, Brecher M. Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study. J. Clin. Psychiatry 70(4), 526–539 (2009).
  • Weisler R, Joyce M, McGill L, Lazarus A, Szamosi J, Eriksson H. Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double- blind, randomized, placebo-controlled study. CNS Spectr. 14(6), 299–313 (2009).
  • Bortnick B, El-Khalili N, Banov M et al. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study. J. Affect. Disord. 128(1–2), 83–94 (2011).
  • Liebowitz M, Lam RW, Lepola U, Datto C, Sweitzer D, Eriksson H. Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial. Depress. Anxiety 27(10), 964–976 (2010).
  • Katila H, Mezhebovsky I, Mulroy A et al. Randomized, double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder. Am. J. Geriatr. Psychiatry 21(8), 1769–1784 (2013).
  • AstraZeneca, Data on file. AstraZeneca plc, London, UK.
  • Huxley N, Baldessarini RJ. Disability and its treatment in bipolar disorder patients. Bipolar Disord. 9(1–2), 183–196 (2007).
  • Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N. Engl. J. Med. 358(3), 252–260 (2008).
  • Lam RW, Kennedy SH, Grigoriadis S et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J. Affect. Disord. 117( Suppl. 117) S26–S43 (2009).
  • Lecrubier Y, Boyer P, Turjanski S, Rein W. Amisulpride versus imipramine and placebo in dysthymia and major depression. Amisulpride Study Group. J. Affect. Disord. 43(2), 95–103 (1997).
  • Ruther E, Degner D, Munzel U et al. Antidepressant action of sulpiride. Results of a placebo-controlled double-blind trial. Pharmacopsychiatry 32(4), 127–135 (1999).
  • Mathews J, Garcia KS, Mintun MA, Sheline YI. Antidepressant efficacy of olanzapine as monotherapy in major depressive disorder, without psychosis: a pilot study. Psychiatry Res. 146(2), 149–155 (2006).
  • Rothschild AJ, Williamson DJ, Tohen MF et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. J. Clin. Psychopharmacol. 24(4), 365–373 (2004).
  • Endicott J, Paulsson B, Gustafsson U, Schiöler H, Hassan M. Quetiapine monotherapy in the treatment of depressive episodes of bipolar I and II disorder: improvements in quality of life and quality of sleep. J. Affect. Disord. 111(2–3), 306–319 (2008).
  • Sheffrin M, Driscoll HC, Lenze EJ et al. Pilot study of augmentation with aripiprazole for incomplete response in late-life depression: getting to remission. J. Clin. Psychiatry 70(2), 208–213 (2009).
  • Steffens DC, Nelson JC, Eudicone JM et al. Efficacy and safety of adjunctive aripiprazole in major depressive disorder in older patients: a pooled subpopulation analysis. Int. J. Geriatr. Psychiatry 26(6), 564–572 (2011).
  • El-Mallakh RS, Briscoe B. Studies of long-term use of antidepressants: how should the data from them be interpreted? CNS Drugs 26(2), 97–109 (2012).
  • Corya SA, Andersen SW, Detke HC et al. Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study. J. Clin. Psychiatry 64(11), 1349–1356 (2003).
  • Rapaport MH, Gharabawi GM, Canuso CM et al. Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology 31(11), 2505–2513 (2006).
  • Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A, Tsai AC. Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS Med. 10(3), e1001403 (2013).
  • Perlis RH, Ostacher M, Fava M, Nierenberg AA, Sachs GS, Rosenbaum JF. Assuring that double-blind is blind. Am. J. Psychiatry 167(3), 250–252 (2010).
  • Montgomery SA. Impact of methodology on the efficacy of extended release quetiapine fumarate in major depressive disorder. Eur. Neuropsychopharmacol. 20( Suppl. 20), S353 (2010).
  • Chen J, Gao K, Kemp DE. Second-generation antipsychotics in major depressive disorder: update and clinical perspective. Curr. Opin. Psychiatry 24(1), 10–17 (2011).
  • Gibbons RD, Hur K, Brown CH, Davis JM, Mann JJ. Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Arch. Gen. Psychiatry 69(6), 572–579 (2012).
  • Patkar AA, Pae CU, Masand PS. Transdermal selegiline: the new generation of monoamine oxidase inhibitors. CNS Spectr. 11(5), 363–375 (2006).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.